No matches
Dermatology

Beyond the Visible: The Cumulative Burden of Prurigo Nodularis

Professor Matthias Augustin emphaizes that prurigo nodularis is a chronic systemic disease with a significant and multifaceted burden, encompassing both visible skin manifestations and hidden psychosocial and physical comorbidities.
Matthias Augustin
MD
Matthias Augustin

Related resources

CSU Burden Related to Chronicity and Patient Journey

CSU Burden Related to Chronicity and Patient Journey

expert video
ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

Podcast
The Importance of Disease Control in Reducing CSU Patient Burden

The Importance of Disease Control in Reducing CSU Patient Burden

expert video
Emerging Therapeutics: Addressing the Gaps in CSU Patient Care

Emerging Therapeutics: Addressing the Gaps in CSU Patient Care

expert video
Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

expert video
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

slide presentation
Targeted Approaches to Holistic Management of PN

Targeted Approaches to Holistic Management of PN

expert video
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

videoanimation
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?

The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?

expert video
Beyond Clinical Control: Targeting Type 2 Inflammation for Improved Patient Outcomes

Beyond Clinical Control: Targeting Type 2 Inflammation for Improved Patient Outcomes

expert video
Cumulative Impact of Uncontrolled Atopic Dermatitis: Skin Inflammation as the Tip of the Iceberg

Cumulative Impact of Uncontrolled Atopic Dermatitis: Skin Inflammation as the Tip of the Iceberg

expert video
On the Surface: Restoring the Skin Barrier in Patients With AD

On the Surface: Restoring the Skin Barrier in Patients With AD

expert video
Charting the Future: Preventing the Atopic March

Charting the Future: Preventing the Atopic March

expert video
How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis

How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis

expert video
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice

Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice

expert video
On the Surface: Restoring the Skin Barrier in Patients with AD

On the Surface: Restoring the Skin Barrier in Patients with AD

expert video
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

expert video
Early Intervention May Have the Potential to Alter the Trajectory of Atopic Dermatitis

Early Intervention May Have the Potential to Alter the Trajectory of Atopic Dermatitis

expert video
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

expert video
Decoding the Clinical Puzzle: Navigating Diagnostic Complexity Across Inflammatory Skin Diseases

Decoding the Clinical Puzzle: Navigating Diagnostic Complexity Across Inflammatory Skin Diseases

expert video
Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases

Shared and Distinct: The Role of Type 2 Inflammation in Skin Diseases

expert video
Time to Act: Reducing the Impact of Uncontrolled Disease Through Early Intervention

Time to Act: Reducing the Impact of Uncontrolled Disease Through Early Intervention

expert video
Beyond Signs and Symptoms: Broadening Treatment Goals in Dermatology

Beyond Signs and Symptoms: Broadening Treatment Goals in Dermatology

expert video
Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment

Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment

expert video
The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD

The Effect of Dupilumab on the Atopic March and Risk of Nonatopic Comorbidities in Pediatric Patients With AD

expert video
Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?

expert video
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

expert video
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation

Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation

expert video
Understanding the Impact of Pediatric Atopic Dermatitis on Vertical Growth

Understanding the Impact of Pediatric Atopic Dermatitis on Vertical Growth

Infographic

Learning objectives

  • Highlight the comprehensive disease burden of prurigo nodularis, encompassing both its visible skin manifestations and hidden psychosocial and systemic comorbidities
Tags
patient burdenchronic inflammationchronic prurituscoexisting diseasestype 2 inflammation
MAT-GLB-2600443 - 1.0 - 02/2026

About this expert

Dermatology

Matthias Augustin

MD

Director, Institute and German Center for Health Services Research in Dermatology and Nursing IVDP

See author’s profile
Matthias Augustin

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: HungaryChange country/region
Beyond the Visible: The Cumulative Burden of Prurigo Nodularis